MAGI2 and lung cancer: In fact, analyses of the TCGA data shows that similarly to what we observe, MAGI2-AS2 is significantly decreased more than 3 fold in bladder, breast, kidney and lung cancers, where it associates with survival, and RP4-781K5.8 (LINC01132) is also increased in liver tumors and associates with survival of glioma, kidney and lung tumors.